Skip to main content

Nonprofit · EIN 83-1794049

TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC

Tax-exempt · PITTSBURGH, PA 15218

Financials

$115K$124K2023$240K$122K2024
Revenue Expenses · by fiscal year end
Financials of TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990$239,968$121,759$118,209$213,822$3,380$210,442
December 31, 2023990-EZ$115,078$123,997-$8,919$92,233$0$92,233
Financial details: 990 for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$0
Program service revenue
$239,968
Investment income
$0
Other revenue
$0

Expenses

Grants and similar amounts paid
$0
Salaries, compensation and benefits (total)
$0
Professional fundraising fees
$0
Accounting fees
$6,060
Occupancy
$94,085
Travel
$1,766
Program services (functional)
$107,160
Management and general (functional)
$14,599

Balance sheet and other

Total assets, start of year
$92,233
Total assets, end of year
$213,822
Total liabilities, end of year
$3,380
Net assets, end of year
$210,442
Gross receipts
$239,968
Employees
0
Volunteers
30
Year formed
2018
State of legal domicile
PA

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensation
Stephen HaleyDirector
Trustee or director
1$0
Kristin AndersonDirector
Trustee or director
1$0
Sonikpreet AulakhDirector
Trustee or director
1$0
Robert BaiocchiDirector
Trustee or director
1$0
Tullia BrunoDirector
Trustee or director
1$0
Maria CastroDirector
Trustee or director
1$0
Grace ChenDirector
Trustee or director
1$0
Prasenjit DeyDirector
Trustee or director
1$0
Scott GerberDirector
Trustee or director
1$0
Alex HuangMeeting Co-Organizer
Trustee or director
1$0
J MelenhorstMeeting Co-Organizer
Trustee or director
1$0
Bradley MillsDirector
Trustee or director
1$0
Scott OlejniczakDirector
Trustee or director
1$0
Emidio PistilliDirector
Trustee or director
1$0
Avery PoseyDirector
Trustee or director
1$0
12 more people on this return
NameTitleHours / weekCompensation
Anthony RulloDirector
Trustee or director
1$0
Melanie RutkowskiDirector
Trustee or director
1$0
Todd SchellDirector
Trustee or director
1$0
Kellie SmithDirector
Trustee or director
1$0
Dario VignaliDirector
Trustee or director
1$0
Hong ZhengDirector
Trustee or director
1$0
Daniel J Powell JrPast President
Officer
1$0
Jonathan BramsonPresident
Officer
2$0
Wei-Zen WeiPast President
Officer
1$0
Heather GibsonSecretary
Officer
2$0
Pawel KalinskiVice President
Officer
2$0
Thomas MaceTreasurer
Officer
2$0
990-EZ for the year ended December 31, 2023: 8 people
NameTitleHours / weekCompensation
Michael T LotzePast President2$0
David J KlinkePresident2$0
Daniel J Powell JrVice President2$0
Jonathan BramsonTreasurer2$0
Stephen HaleyIndustry2$0
Wei-Zen WeiSecretary2$0
Elizabeth RepaskyPast President2$0
Sharon CoutchMeeting Organizer2$0

Address and contacts

Address (IRS master file)
CO 1227 SOUTH BRADDOCK AVENUE, PITTSBURGH, PA 15218-0000
In care of
% JONATHAN BRAMSON
Mailing address (990-N for 2021)
co 1227 South Braddock Avenue, Pittsburgh PA 15218
Principal officer (990-N for 2021)
Michael T Lotze, 5134 Westminster Place, Pittsburgh PA 15232
Signed the 990
JONATHAN BRAMSON, President
Return prepared by
Law Offices of Kathleen D Schneider

Mission

Dissemination of information regarding the prevention, treatment, and cure of cancer, integrating cancer biology and tumor immunology. Promoting research, clinical collaborations, enhanced partnerships with industry, and training of the next generation of scientists.

990 for the year ended December 31, 2024

Program accomplishments

  • The annual TRCCC meeting provides a unique opportunity for trainees to present and interact in a supportive environment, enhancing their learning experience, skills as medical professionals, and ability to push boudaries in the medical field. The 2024 Meeting was entitled Pushing Immunotherapeutic Boundaries, and consisted of numerous guest speakers from leaders within the immunotherapeutic field and provided atendees with a spatial transcriptomics workshop to learn innovative techniques on current spatial transcriptomics platforms and data analsysis, as well as learn about related emerging technologies. Other topics included, but are not limited to: the impact of the tumor microenvironment on anti-tumor immunity, novel targeting of the immune response in cancer and a discussion of gender in science and academia.
    Expenses $107,160 · revenue $178,368
  • The TRCCC is composed of Cancer Centers, or Academic Institutions with a major focus on cancer research, within an easily accessible distance to the yearly meeting site that advances the dissemination of research and new clinical trials towards the prevention, treatment and cure of cancer, with an emphasis on the study of Immuno-Oncology, immunotherapy and other biological therapies of cancer. Each member institution may choose up to two faculty members to provide their current research in platform presentations, and to have their trainees present short talks and/or posters, at the yearly meeting. Each member institution also can have their Center participate in any clinical trials that are developed at TRC3 centers and other types of inter-institutional scientific collaborations and training opportunities, such as joint NIH training grants, NCI SPORES and P01s.
    revenue $61,600

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990-EZ on file

IRS record

EIN
83-1794049
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (509(a)(2))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2021
Accounting year ends
December
Files
Form 990 or 990-EZ
Assets (IRS master file)
$213,822
Income (IRS master file)
$239,968

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2024$239,968$121,759$213,822XML
990-EZDecember 2023$115,078$123,997$92,233XML
990-EZDecember 2022–––IRS
990-N for 2021
Officer: Michael T Lotze
December 31, 2021≤ $50,000 receipts––e-Postcard
990-N for 2018
Officer: Elizabeth A Repasky
December 31, 2018≤ $50,000 receipts––e-Postcard

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 83-1794049).

Questions about TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC

What is the EIN of TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC?
The employer identification number (EIN) of TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC is 83-1794049.
Is TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2021.
Are donations to TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2024.
Who is the principal officer of TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC?
The 990-N for 2021 names Michael T Lotze.
Who are the officers and directors of TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC?
The 990 for the year ended December 31, 2024 lists 27 people; 0 received compensation from the organization.
How much revenue does TRANSLATIONAL RESEARCH CANCER CENTER CONSORTIUM INC have?
On its 990 for the year ended December 31, 2024 it reported revenue of $239,968, expenses of $121,759 and total assets of $213,822 at year end.

Other nonprofits in PITTSBURGH

All nonprofits in PITTSBURGH · Pennsylvania · Voluntary health associations and medical disciplines